Morning Market Movers
Revance Therapeutics (NASDAQ: RVNC) shares gained 21.91% to $34.89 after the company reported positive results from the RT002 Phase 1/2 study in glabellar (frown) lines.
Intricon (NASDAQ: IIN) shares jumped 18.30% to $5.50 after the company reported Q1 results.
Centene (NYSE: CNC) jumped 15.83% to $66.36 on upbeat quarterly results. Centene reported its Q1 earnings of $0.57 per share on revenue of $3.46 billion.
Allergan (NYSE: AGN) jumped 15.67% to $164.25 on buyout offer.
AxoGen (NASDAQ: AXGN) climbed 14.29% to $3.20. AxoGen is expected to report its Q1 financial results on April 30, 2014.
Dyax (NASDAQ: DYAX) surged 12.64% to $7.55. Dyax is expected to report its Q1 results on April 30, 2014.
Rent-A-Center (NASDAQ: RCII) surged 9.82% to $28.30 after the company reported upbeat quarterly earnings and issued a strong FY14 earnings forecast.
Evoke Pharma (NASDAQ: EVOK) shares rose 9.41% to $8.60 after the company initiated Phase 3 clinical trial of EVK-001 for the treatment of gastroparesis. Laidlaw & Co. initiated coverage on the stock with a Buy rating.
Netflix (NASDAQ: NFLX) shares rose 9.07% to $380.11 after the company reported better-than-expected first-quarter earnings and issued a strong outlook. Netflix reported its quarterly earnings of $0.86 per share on revenue of $1.27 billion. However, analysts were expecting earnings of $0.81 per share on revenue of $1.27 billion. Raymond James upgraded Netflix from Market Perform to Outperform.
Harley-Davidson (NYSE: HOG) gained 7.39% to $72.53 after the company reported upbeat first-quarter earnings. Harley-Davidson's quarterly earnings surged to $265.9 million, or $1.21 per share, from $224.1 million, or $0.99 per share, in the year-ago quarter.
Valeant Pharmaceuticals International (NYSE: VRX) shares climbed 5.27% to $132.65 after the company proposed to combine with Allergan (NYSE: AGN) for $48.30 per share in cash and 0.83 shares of Valeant common stock.
Intuitive Surgical (NASDAQ: ISRG) rose 4.59% to $429.99 after the company announced the FDA clearance of da Vinci(R) Sp(TM) Surgical System.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.